FDA Accepts Supplement Application for ONTRUZANT (Trastuzumab-DTTB)
The FDA has accepted the supplemental application for ONTRUZANT, a biosimilar to trastuzumab.
Therapeutic Area
Therapeutic area intelligence for Biosimilar with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.